Short CommunicationDown-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta

Add time:08/30/2019    Source:sciencedirect.com

This study aimed to examine the expression of TYK2, CBLB and LMP7 genes at both mRNA and protein levels in relapsing-remitting MS (RRMS) patients in compare with healthy controls. Seventy-eight RRMS patients treated with IFNβ-1a and 79 age- and ethnic-matched healthy subjects were studied. The mRNA expression levels of TYK2, CBLB and LMP7 in PBMCs were quantified by real-time PCR and plasma concentrations of three molecules were measured by ELISA. Results were compared between patients and controls, IFNβ-responders and non-responders. Forty-nine of 78 patients were classified as IFNβ-responders and 29 cases were non-responders. Significantly down-regulated expression of TYK2, CBLB and LMP7 genes was found in the patients group versus controls (P < 0.001). Decreased plasma levels of three molecules were observed in patients compared to controls (P < 0.001). IFNβ-responders had significantly higher expressions for CBLB (P = 0.001) and LMP7 (P = 0.02) than non-responders. Also, we observed increased expressions of LMP7 (P = 0.39) and CBLB (P = 0.02) genes in patients under 30y and increased expression of TYK2 in patients > 40 years (P = 0.002). Our results suggest that expression analysis of TYK2, CBLB and LMP7 genes could be useful for evaluation of T cells immunity and clinical response to IFNβ-therapy in RRMS patients.

We also recommend Trading Suppliers and Manufacturers of tyk2 protein (cas 132966-45-1). Pls Click Website Link as below: cas 132966-45-1 suppliers

Prev:Original ArticleDi (2-ethylhexyl) phthalate Disorders Lipid Metabolism via TYK2/STAT1 and Autophagy in Rats
Next:Computer-aided identification of potential TYK2 inhibitors from drug database)